Brokers Offer Predictions for INTS FY2029 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Stock analysts at Brookline Capital Markets boosted their FY2029 earnings per share (EPS) estimates for shares of Intensity Therapeutics in a note issued to investors on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of $7.33 for the year, up from their prior estimate of $7.32. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.46) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ FY2030 earnings at $12.72 EPS.

A number of other research firms have also recently issued reports on INTS. Weiss Ratings cut shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Freedom Capital raised shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th. Finally, Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intensity Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Intensity Therapeutics Price Performance

INTS stock opened at $4.77 on Thursday. The stock has a market capitalization of $12.88 million, a PE ratio of -0.47 and a beta of 2.94. The company’s 50-day moving average is $5.91 and its 200-day moving average is $8.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. Intensity Therapeutics has a 1 year low of $4.63 and a 1 year high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12.

Hedge Funds Weigh In On Intensity Therapeutics

Several large investors have recently added to or reduced their stakes in INTS. Mesirow Financial Investment Management Inc. lifted its position in shares of Intensity Therapeutics by 25.5% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after buying an additional 51,000 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $26,000. Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $41,000. State Street Corp lifted its position in shares of Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares in the last quarter. Finally, Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $63,000. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.